Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS: CLS-AX in Neovascular AMD
NCT04626128Phase 2Completed
- Sponsor
- Clearside Biomedical
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Injectable Hydrogels, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of CLS-AX in neovascular age-related macular degeneration (NVAMD), sponsored by Clearside Biomedical. Started Dec 2020; status: completed.
02
Drugs
CLS-AX
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04626128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626128.